Anthem Biosciences Ltd. made an entry on Dalal Street on Monday, July 21, 2025, with its shares listing at a 27% premium to the issue price. On the BSE, the stock debuted at ₹723.10, while on the NSE, it opened at ₹723.05 both higher than the IPO price of ₹570 per share.
The ₹3,395 crore initial public offering (IPO), which ran from July 14 to July 16, was an Offer for Sale (OFS) and attracted investor participation across categories. The issue was subscribed 67.42 times overall, with Qualified Institutional Buyers (QIBs) leading the charge at 192.80 times, followed by Non-Institutional Investors (NIIs) at 44.70 times, and the retail category at 5.98 times.
The company also raised ₹1,016 crore from anchor investors ahead of the public issue.
Since the entire IPO was an OFS, Anthem Biosciences will not receive any proceeds from the issue. The funds, excluding issue-related expenses, will go directly to the selling shareholders.
Founded in 2006, Anthem Biosciences operates as a Contract Research, Development, and Manufacturing Organisation (CRDMO). The company provides comprehensive, end-to-end solutions to clients in the pharmaceutical and biotech sectors. Its services span the full drug development lifecycle from early-stage research to commercial-scale manufacturing offered through an integrated platform that enhances efficiency and reduces compliance complexity.
Read More: NLC Subsidiary, NIRL to Launch IPO in Q2 of Next Fiscal to Raise ₹4,000 Crore.
While the company itself does not gain proceeds from the IPO due to its Offer for Sale structure, its performance on the bourses indicates confidence in its business model and sector outlook. Investors may continue to monitor the stock’s performance and company developments in the coming quarters for a clearer long-term view.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 21, 2025, 10:40 AM IST
Neha Dubey
Neha Dubey is a Content Analyst with 3 years of experience in financial journalism, having written for a leading newswire agency and multiple newspapers. At Angel One, she creates daily content on finance and the economy. Neha holds a degree in Economics and a Master’s in Journalism.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
